drugset / Trial / NCT02733848
CREON for the Treatment of Post-RYGB Hypoglycemia
Non-randomizedCrossoverSingle-blindTreatment
Summary
Hypoglycemia is an increasingly recognized complication of Roux-en-Y gastric bypass (RYGB) that is poorly understood and difficult to treat. Investigators hypothesize that after RYGB some patients have incomplete carbohydrate absorption in the small intestine which leads to inconsistent glucose levels and hypoglycemia during oral consumption of a meal. Investigators further hypothesize that pancreatic enzyme supplementation with (Creon) during meals and snacks will improve carbohydrate absorption and lead to more stable glucose levels in patients with post-RYGB hypoglycemia.
Timeline
- Start
- 2014-02
- Primary completion
- 2018-01-31
- Completion
- 2018-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pancrelipase | Protein / enzyme biologic | 500 iu/kg | — |